<DOC>
	<DOCNO>NCT02316028</DOCNO>
	<brief_summary>Despite advance medical treatment unresectable liver metastasis colorectal cancer currently curative treatment option available patient . Decitabine cytidine analog proven anti-neoplastic activity patient acute myeloid leukemia myelodysplastic syndrome . Decitabine cause demethylation DNA strand replicate cell . Hereby decitabine treatment demethylates promoter region tumor suppressor- cancer testis antigen encode gene lead expression gene cancer cell . The hepatic arterial route administration cytotoxic drug widely explore treatment colorectal cancer liver metastases metastasis depend blood flow artery ( oppose normal liver tissue mainly dependent portal vein ) . By investigate administration decitabine hepatic arterial infusion investigator intend explore potential advantage minimize systemic exposure ( toxicity ) maximize concentration decitabine within liver metastasis . The primary objective phase I establish recommend dose decitabine HAI use phase II trial . The important secondary objective document effect decitabine HAI expression cancer testis antigens colorectal cancer cell , serve reference potential exploration decitabine HAI combination cancer immunotherapy</brief_summary>
	<brief_title>Phase I : Decitabine Hepatic Arterial Infusion ( HAI ) Unresectable Liver Metastases Colorectal Cancer ( CRC )</brief_title>
	<detailed_description>This clinical trial recruit eligible patient diagnose unresectable liver-predominant colorectal cancer metastases experience progression disease follow standard care treatment . Unless patient already dispose hepatic arterial catheter , undergo placement permanent hepatic artery catheter ( laparoscopic surgery ) . During surgical procedure biopsy make colorectal cancer liver metastasis . Decitabine administer daily 1-hour IV infusion 5 consecutive day , every 4weeks . Two week first day administration decitabine , CT-guided biopsy liver metastasis perform order obtain tumor tissue histopathological analysis DNA/RNA extraction purpose methylation specific Polymerase Chain Reaction ( PCR ) reverse transcriptase PCR assessment demethylation expression cancer-testis antigen encode gene . Blood sample collection `` cell-free DNA '' White Blood Cell ( WBC ) purpose DNA/RNA extraction analysis methylation specific PCR reverse transcriptase PCR assessment demethylation expression cancer-testis antigen encode gene obtain weekly decitabine treatment . The dose decitabine escalate subsequent patient cohort enrol phase I trial ( see rule dose escalation ) . Study treatment continue unacceptable toxicity , progressive disease patient refusal .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histological documentation colorectal adenocarcinoma CRC stage IV predominant unresectable liver metastasis least one measurable metastatic liver lesion Performance status WHO criteria &lt; 2 . Laboratory value : absolute neutrophil count ( ANC ) count &gt; 1500 /mm³ , Platelet count &gt; 100 000 /mm³ , Lymphocytes &gt; 800 /mm³ , Serum creatinine &lt; 2.0 mg/dl creatinine clearance &gt; 40 ml/min , Serum bilirubin &lt; 2.0 mg/dl Progressive disease follow standard care palliative systemic chemotherapy able give write informed consent . No prior radiotherapy target liver lesions No previous history gastric hepatobiliary surgery ( except simple cholecystectomy , No concurrent liver disease serious medical disease condition No concomitant use investigational drug . No preexist neuropathy severity &gt; grade 1 WHO toxicity scale . No previous concurrent malignancy except adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin malignancy give potentially curative treatment 5 year study entry No pregnant breastfeed female patient , use effective contraceptive risk conception exist study treatment . No candidate resection CRC metastases curative intent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>decitabine</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>hepatic arterial infusion</keyword>
</DOC>